All In Biotech

Drug Trial Radar · NCT03178084

Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio

The Effects of Maraviroc Versus Efavirenz in Combination With Zidovudine/Abacavir on the CD4/CD8 Ratio in Treatment-naïve HIV-infected Individuals

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 721 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

721

Actual

Start

Oct 15, 2014

Primary completion

Nov 5, 2016

Study completion Mar 7, 2017

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A low CD4/CD8 ratio is considered a surrogate marker of immunosenescence and is an independent predictor of non-AIDS-related morbidity and mortality. Given the strong clinical implications the impact of different regimens on the CD4/CD8 ratio recovery needs to be analyzed. The MERIT study is a completed a randomized, double-blind, multicenter phase IIb/III study with an open-label extension phase (240-week follow-up) to assess the efficacy of zidovudine/lamivudine in combination with maraviroc (MVC) or efavirenz (EFV) in treatment-naïve patients. Anonymised patient level data of the MERIT trial to compare the trajectories of the CD4/CD8 ratio of participants treated with maraviroc vs. efavirenz will be used.

Conditions

  • HIV/AIDS

Interventions

  • Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BIDDrug

    maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily

  • Efavirenz QD + Zidovudine/Lamivudine BIDDrug

    efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)

  • Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QDDrug

    maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in CD4/CD8 ratioTime frame: From baseline to week 120

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.